BIOMAT Database Logo BIOMAT Database Logo

Long-term medical management of hypertrophic obstructive cardiomyopathy. 1978

M J Frank, and A M Abdulla, and M I Canedo, and R E Saylors

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010138 Pacemaker, Artificial A device designed to stimulate, by electric impulses, contraction of the heart muscles. It may be temporary (external) or permanent (internal or internal-external). Cardiac Pacemaker, Artificial,Artificial Cardiac Pacemaker,Artificial Cardiac Pacemakers,Artificial Pacemaker,Artificial Pacemakers,Cardiac Pacemakers, Artificial,Pacemaker, Artificial Cardiac,Pacemakers, Artificial,Pacemakers, Artificial Cardiac
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D002312 Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). Cardiomyopathy, Hypertrophic Obstructive,Cardiomyopathies, Hypertrophic,Cardiomyopathies, Hypertrophic Obstructive,Hypertrophic Cardiomyopathies,Hypertrophic Cardiomyopathy,Hypertrophic Obstructive Cardiomyopathies,Hypertrophic Obstructive Cardiomyopathy,Obstructive Cardiomyopathies, Hypertrophic,Obstructive Cardiomyopathy, Hypertrophic
D004244 Dizziness An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness. Lightheadedness,Orthostasis,Dizzyness,Light-Headedness,Light Headedness
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

M J Frank, and A M Abdulla, and M I Canedo, and R E Saylors
Management of symptomatic hypertrophic obstructive cardiomyopathy--long-term results after surgical therapy.
August 1999, The Thoracic and cardiovascular surgeon,
M J Frank, and A M Abdulla, and M I Canedo, and R E Saylors
Long-term benefits of pacing in obstructive hypertrophic cardiomyopathy.
March 2010, Heart (British Cardiac Society),
M J Frank, and A M Abdulla, and M I Canedo, and R E Saylors
Long-term treatment of hypertrophic obstructive cardiomyopathy--usefulness of verapamil.
November 1983, European heart journal,
M J Frank, and A M Abdulla, and M I Canedo, and R E Saylors
Long-term outcomes of septal reduction for obstructive hypertrophic cardiomyopathy.
July 2015, Journal of cardiology,
M J Frank, and A M Abdulla, and M I Canedo, and R E Saylors
Surgical management of hypertrophic obstructive cardiomyopathy.
September 2020, General thoracic and cardiovascular surgery,
M J Frank, and A M Abdulla, and M I Canedo, and R E Saylors
Hypertrophic obstructive cardiomyopathy: problems of management.
July 1997, Chest,
M J Frank, and A M Abdulla, and M I Canedo, and R E Saylors
Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myectomy.
May 1998, The Annals of thoracic surgery,
M J Frank, and A M Abdulla, and M I Canedo, and R E Saylors
Medical management of hypertrophic cardiomyopathy.
January 2010, Reviews in cardiovascular medicine,
M J Frank, and A M Abdulla, and M I Canedo, and R E Saylors
[Clinical features and long-term outcome comparison of patients with midventricular obstructive hypertrophic cardiomyopathy and apical hypertrophic cardiomyopathy].
October 2015, Zhonghua xin xue guan bing za zhi,
M J Frank, and A M Abdulla, and M I Canedo, and R E Saylors
Predictors of short-term and long-term effects of mavacamten in obstructive hypertrophic cardiomyopathy.
May 2024, Progress in cardiovascular diseases,
Copied contents to your clipboard!